Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles

B. King; Becka Hughes; S. Navarro-marchal; V.g. Brunton; E. Poradosu; Neil O. Carragher; A. Unciti-broceta

doi:10.1016/S0959-8049(22)01103-0

Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles

B. King, Becka Hughes, S. Navarro-marchal, V.g. Brunton, E. Poradosu, Neil O. Carragher, A. Unciti-broceta

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	S113
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)01103-0
Publication status	Published - 1 Oct 2022

Access to Document

10.1016/S0959-8049(22)01103-0

https://linkinghub.elsevier.com/retrieve/pii/S0959804922011030

Edinburgh Drug Discovery
Asier Unciti-Broceta (Manager), Scott Webster (Manager) & Neil Carragher (Manager)
Deanery of Molecular, Genetic and Population Health Sciences
Facility/equipment: Facility

Cite this

@article{c8374f4535444c90ab02d6fa872040c5,

title = "Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles",

author = "B. King and Becka Hughes and S. Navarro-marchal and V.g. Brunton and E. Poradosu and Carragher, {Neil O.} and A. Unciti-broceta",

note = "Funding Information: Corporate-sponsored Research: Research study funded by Nuvectis Pharma ",

year = "2022",

month = oct,

day = "1",

doi = "10.1016/S0959-8049(22)01103-0",

language = "English",

volume = "174",

pages = "S113",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon Press",

}

TY - JOUR

T1 - Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles

AU - King, B.

AU - Hughes, Becka

AU - Navarro-marchal, S.

AU - Brunton, V.g.

AU - Poradosu, E.

AU - Carragher, Neil O.

AU - Unciti-broceta, A.

N1 - Funding Information: Corporate-sponsored Research: Research study funded by Nuvectis Pharma

PY - 2022/10/1

Y1 - 2022/10/1

U2 - 10.1016/S0959-8049(22)01103-0

DO - 10.1016/S0959-8049(22)01103-0

M3 - Article

SN - 0959-8049

VL - 174

SP - S113

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles

Access to Document

Equipment

Edinburgh Drug Discovery

Cite this